Somerville, Massachusetts-based Finch Therapeutics closed a $90 million Series D financing, with plans to use the funds to advance the company’s lead candidate CP101 for recurrent C. difficile infection through the final stages of clinical development and regulatory submission.
Fernando Fernandez, Managing Director of FCB Health Network’s BX – Brand Experience Design Group, talked to Med Ad News about how COVID-19 has changed the way people interact with brands, how branding innovations such as audio and motion identities are making their way to pharma, and other topics.
The U.S. Food and Drug Administration accepted Copenhagen, Denmark-based Orphazyme’s New Drug Application (NDA) for arimoclomol for the treatment of Niemann-Pick disease Type C.
San Francisco-based Unity Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology.
Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.
Although it’s increasingly likely that one of the Covid-19 vaccines being tested will be approved or receive Emergency Use Authorization (EUA) before the end of 2020, experts are increasingly warning that widespread distribution may take a much longer time.
Takeda Pharmaceutical opened a new 24,000-square-foot R&D cell therapy manufacturing facility in Boston at the site of the company’s R&D headquarters.
U.S-based cancer testing startup Grail Inc., a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) with the U.S. Securities and Exchange Commission.
AstraZeneca resumed the company’s Covid-19 vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Eli Lilly and Co. said the company’s rheumatoid arthritis drug baricitinib shortened the recovery time for hospitalized Covid-19 patients also given Gilead Sciences Inc.’s antiviral remdesivir.